Literature DB >> 17006653

[Sleep in neurodegenerative disorders].

S Happe1, G Mayer.   

Abstract

Neurodegenerative disorders are a group of heterogeneous, progressive disorders of varying etiology that affect one or more systems. They occur predominantly at older age, during which the structure and amount of sleep undergo changes. Neurodegenerative processes cause structural changes of the sleep/wake generators in the brainstem which result in disorders such as daytime sleepiness, insomnia, sleep-related movement and breathing disturbances, and disorders of the circadian rhythms. Some sleep disorders manifest years before the onset of neurodegenerative disorders and may serve as predictors. Polysomnography shows sleep fragmentation, tonic or phasic movements of the extremities, alteration of respiratory muscles, reduced slow wave sleep, REM sleep absence or without muscle atonia, increased arousal or wake activity, epileptiform EEG activity, and changes in sleep-related breathing. Very frequently, REM sleep behaviour disorder is associated with neurodegenerative disorders. In this overview we present symptoms, pathophysiology, and polysomnographic findings of sleep disorders in prevalent neurodegenerative disorders.

Entities:  

Mesh:

Year:  2006        PMID: 17006653     DOI: 10.1007/s00115-006-2151-6

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  35 in total

Review 1.  Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD.

Authors:  David B Rye; Joseph Jankovic
Journal:  Neurology       Date:  2002-02-12       Impact factor: 9.910

2.  REM sleep behavior disorder in sleep-disordered patients with versus without Parkinson's disease: is there a need for polysomnography?

Authors:  I Eisensehr; H v Lindeiner; M Jäger; S Noachtar
Journal:  J Neurol Sci       Date:  2001-05-01       Impact factor: 3.181

3.  Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD.

Authors:  A Iranzo; J Santamaría; D B Rye; F Valldeoriola; M J Martí; E Muñoz; I Vilaseca; E Tolosa
Journal:  Neurology       Date:  2005-07-26       Impact factor: 9.910

4.  Changes in nocturnal sleep in Huntington's and Parkinson's disease.

Authors:  W Emser; M Brenner; T Stober; K Schimrigk
Journal:  J Neurol       Date:  1988-01       Impact factor: 4.849

5.  Increased muscle activity during rapid eye movement sleep correlates with decrease of striatal presynaptic dopamine transporters. IPT and IBZM SPECT imaging in subclinical and clinically manifest idiopathic REM sleep behavior disorder, Parkinson's disease, and controls.

Authors:  Ilonka Eisensehr; Reiner Linke; Klaus Tatsch; Bita Kharraz; Josef F Gildehaus; Christian T Wetter; Claudia Trenkwalder; Johannes Schwarz; Soheyl Noachtar
Journal:  Sleep       Date:  2003-08-01       Impact factor: 5.849

Review 6.  REM sleep behavior disorder in Parkinson's disease and dementia with Lewy bodies.

Authors:  Bradley F Boeve; Michael H Silber; Tanis J Ferman
Journal:  J Geriatr Psychiatry Neurol       Date:  2004-09       Impact factor: 2.680

Review 7.  Restless legs syndrome and PD: a review of the evidence for a possible association.

Authors:  Diego Garcia-Borreguero; Per Odin; Carolina Serrano
Journal:  Neurology       Date:  2003-09-23       Impact factor: 9.910

8.  Contributions of dopaminergic drugs and disease severity to daytime sleepiness in Parkinson disease.

Authors:  Padraig E O'Suilleabhain; Richard B Dewey
Journal:  Arch Neurol       Date:  2002-06

9.  [18F]fluorodopa uptake in the upper brainstem measured with positron emission tomography correlates with decreased REM sleep duration in early Parkinson's disease.

Authors:  Ruediger Hilker; Noushin Razai; Mehran Ghaemi; Simon Weisenbach; Jobst Rudolf; Brigitte Szelies; Wolf-Dieter Heiss
Journal:  Clin Neurol Neurosurg       Date:  2003-09       Impact factor: 1.876

10.  Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT.

Authors:  K Stiasny-Kolster; Y Doerr; J C Möller; H Höffken; T M Behr; W H Oertel; G Mayer
Journal:  Brain       Date:  2004-11-17       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.